Contribution: Industrial Research Assistance Program – Contributions to Firms
Ripple Therapeutics Corporation
$300,000.00
RTC-PG Sustained Release Prostaglandins
FY 2024-25 · 2024-04-01
Summary
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The Ripple pipeline currently has a variety of conjugates under development targeting key ocular indications such as glaucoma, DME and GA-AMD. Scientific and engineering resources will perform work on the manufacturability of Ripple’s prostaglandin conjugates (RTC-PGs) for the treatment of Primary Open Angle Glaucoma. The project will require analysis of data generated from chemistry, manufacturing and controls (CMC) development to develop the manufacturing know-how for a robust and sustainable licensing and commercialization process that can be applied to all pipeline products.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
760459073
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2024-04-01 | 2024-25 | $250,000.00 |
| 2 | 2024-04-01 | 2024-25 | $300,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 50,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 50 000 dollars.
Agreement End Date
2025-01-31
Agreement Number
1018655
Agreement Start Date
2024-04-01
Agreement Title
RTC-PG Sustained Release Prostaglandins
Agreement Title (French)
Prostaglandines à libération prolongée RTC-PG
Agreement Type
Contribution
Agreement Value
$300,000.00
Amendment Date
2025-01-15
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The Ripple pipeline currently has a variety of conjugates under development targeting key ocular indications such as glaucoma, DME and GA-AMD. Scientific and engineering resources will perform work on the manufacturability of Ripple’s prostaglandin conjugates (RTC-PGs) for the treatment of Primary Open Angle Glaucoma. The project will require analysis of data generated from chemistry, manufacturing and controls (CMC) development to develop the manufacturing know-how for a robust and sustainable licensing and commercialization process that can be applied to all pipeline products.
Description (French)
Ripple Therapeutics Corporation est une société privée en phase clinique qui se concentre sur les produits thérapeutiques ophtalmiques à libération contrôlée et durable. Le pipeline de Ripple comprend actuellement une variété de conjugués en cours de développement ciblant des indications oculaires clés telles que le glaucome, l’œdème maculaire diabétique et l’atrophie géographique (stade avancé de la dégénérescence maculaire liée à l’âge). Les ressources scientifiques et techniques effectueront des travaux sur la fabricabilité des conjugués de prostaglandine de Ripple (RTC-PGs) pour le traitement du glaucome primaire à angle ouvert. Le projet nécessitera l’analyse des données générées par le développement de la chimie, de la fabrication et des contrôles (CMC) afin de développer le savoir-faire en matière de fabrication pour un processus de licence et de commercialisation robuste et durable pouvant être appliqué à tous les produits en cours de développement.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
32541
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
760459073
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Ripple Therapeutics Corporation
Recipient Operating Name
Ripple Therapeutics
Recipient Postal Code
M5G 1L7
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2024-2025-Q1-1018655
